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Associations between MTHFR 1793G>A and plasma total
homocysteine, folate, and vitamin B12 in kidney transplant
recipients.
Background. Currently, no evidence is available on the puta-
tive associations between a novel single nucleotide polymor-
phism of the 5,10-methylenetetrahydrofolate reductase gene
MTHFR 1793G>A and plasma levels of vitamin B12, folate,
or total homocysteine (tHcy).
Methods. In a cross-sectional study of 730 kidney allograft
recipients, patients were categorized by MTHFR 1793G>A
genotype. In univariate and multivariate linear regression mod-
els that allowed the outcome variables vitamin B12, folate, and
tHcy plasma levels to follow a gamma distribution, we tested for
possible associations of allelic variants of MTHFR 1793G>A
and these three dependent variables. As hypothesized in previ-
ous work, we specifically evaluated possible effect modification
between the MTHFR 1793G>A and 1298A>C mutations on
these outcomes.
Results. The allele frequency for MTHFR 1793G>A was
0.052. Heterozygosity (N = 72) or homozygosity (N = 2)
for MTHFR 1793G>A was not independently associated with
plasma levels of vitamin B12 (P = 0.33) or tHcy (P = 0.70), but a
borderline association with higher folate concentrations was de-
tected (folate = 1.91 nmol/L) (95% CI −0.03 to 3.86 nmol/L)
(P = 0.05). Further, we found strong and significant positive in-
teractions between the MTHFR 1793G>A and 1298A>C mu-
tations on vitamin B12 concentrations.
Conclusion. Higher folate concentrations in kidney trans-
plant recipients with MTHFR 1793GA or 1793AA and
markedly higher concentrations of vitamin B12 in patients with
combined MTHFR 1793G>A and 1298A>C mutations may
contribute to the survival advantage that has been postulated
for such patients showing these genotypes.
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Elevated plasma total homocysteine (tHcy) is an es-
tablished risk factor for various cardiovascular outcomes
as well as for neural tube defects [1, 2]. The relevance
of tHcy as a risk factor is even more pronounced in pa-
tients with chronic kidney disease, or on renal replace-
ment therapy, due to an altered Hcy metabolism in such
patients [3]. Mutations in specific genes encoding en-
zymes are involved in these metabolic abnormalities. It
has been hypothesized for several of these mutations to
be related to increases in tHcy plasma levels, either di-
rectly, or via changes in other factors involved in the Hcy
metabolism, such as folate or vitamin B12. While there is
wide agreement that the mutation at nucleotide position
677 in the 5,10-methylenetetrahydrofolate reductase
gene (MTHFR 677C>T) is related to hyperhomocys-
teinemia [4], such effects could not be demonstrated
for other single nucleotide polymorphisms (SNPs) in the
MTHFR encoding gene (e.g., 1298A>C) or those encod-
ing other enzymes such as the reduced folate carrier 1
gene (RFC1 80G>A) [5, 6], the glutamate carboxypep-
tidase II gene (GCP2 1561C>T) [5, 6], the methionine
synthase reductase gene (MTRR 66A>G) [7], and the
transcobalamin II gene (TCN2 776C>G) [8, 9] among
end-stage renal disease (ESRD) or kidney transplant pa-
tients.
Recently, another polymorphism, MTHFR 1793G>A,
was first described [10]. To date, it is unknown whether
MTHFR 1793G>A affects the functional activity of
the enzyme. Such information would be of great inter-
est in light of a recent study that examined patterns
of co-occurrence of three polymorphisms of MTHFR
(677C>T, 1298A>C, and 1793G>A) in a large sample
of kidney transplant recipients [11]. In that study, higher
prevalences than expected of dual, triple and quadru-
ple mutations of MTHFR were found (1298AC/1793GA,
1298CC/1793GA, and 1298CC/1793AA) (P < 0.001)
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Table 1. Frequencies of MTHFR 1298A>C and 1793G>A allelic
variants (observed and expected cell counts)
MTHFR 1793Observed
(expected) GG GA AA Total
MTHFR 1298 AA 319 2 0 321
(288.5) (31.7) (0.9)
AC 288 53 0 341
(306.4) (33.6) (0.9)
CC 49 17 2 68
(61.1) (6.7) (0.2)
Total 656 72 2 730
This table corresponds directly with Table 3 in reference [11]. The one patient
that was excluded from all association studies was in MTHFR 1298AA and
1793GG.
(Table 1). Based on these findings, the hypothesis was
raised that a mutually stabilizing effect might be opera-
tional that yielded a survival benefit for carriers of these
allele combinations [11]. This effect could be mediated
via beneficial changes in the tHcy, folate, or vitamin B12
concentrations.
The present study was designed to address these ques-
tions. We specifically aimed to test the hypothesis whether
allelic variants of MTHFR 1793G>A were independently
associated with vitamin B12, folate, or tHcy plasma lev-
els in kidney transplant recipients. Further, we sought to
test for interaction between the MTHFR 1298A>C and
1793G>A allelic variants on these outcomes.
METHODS
Study population
We conducted a cross-sectional study of 733 kidney
allograft recipients who received routine follow-up at a
large academic transplant center. The detailed rules for
study inclusion have been published elsewhere [12]. Ma-
terial for full genetic analysis was unavailable for three
individuals, which left a final study population of 730 pa-
tients. None of the patients was prescribed routine folic
acid or vitamin B supplementation. However, one patient
had excessively high vitamin B12 concentrations, possibly
indicating self-medication. We decided a priori to exclude
this patient from all association studies (Note: including
this patient influenced the regression results substantially,
as found by post hoc analyses that included the patient).
All patients provided written informed consent accord-
ing to the Declaration of Helsinki and the Austrian Law
on Gene Technology.
Biochemical methods
Fasting citrated blood was immediately placed on
ice and centrifuged at 2000 × g at 4◦C (20 minutes)
within 60 minutes. Plasma aliquots and 500 lL of cit-
rated blood for isolation of DNA were snap frozen and
stored at −70◦C. Plasma concentrations of tHcy (free plus
protein-bound Hcy) [13] were determined by automated
high-performance liquid chromatography (HPLC) with
reversed-phase separation and fluorescence detection us-
ing tri-n-butylphosphine as a reducing agent. Intra-assay
variability was between 1.4% and 1.7% and interassay
variability was between 1.5% and 1.9% for tHcy con-
centrations of 15.9 and 6.9 lmol/L, respectively. Folate
and vitamin B12 plasma levels were measured with a ra-
dioassay (SimulTRAC-SNB) (ICN Pharmaceuticals Inc.,
Costa Mesa, CA, USA). Interassay variability was 4% to
5% for folate measurements and 4% to 6% for vitamin
B12 levels. The creatinine clearance was calculated using
the equation of Cockcroft and Gault and standardized to
a body surface area of 1.73 m2 [14].
Genotyping
Identification of the MTHFR 677C>T transition and
the MTHFR 1298A>C transversion was conducted using
restriction fragment length polymorphism (RFLP) anal-
ysis and the polymerase chain reaction (PCR) primers
and restriction enzymes Hinf I and Fnu4HI published
by Frosst et al [15] and Weisberg et al [16]. We se-
lected the RFLP system of Weisberg et al since this
test system allowed for a clear descrimination be-
ween MTHFR 1298A>C and the silent polymorphism
MTHFR 1317T>C.
The 1793G>A mutation was analyzed in PCR prod-
ucts that had been amplified with the primers published
by Rady et al [10]. MTHFR 1793G>A abolishes the re-
striction site for BsrbI. After cleavage with BsrbI sam-
ples without mutation show two fragments of 233 and 77
bp, whereas samples with mutations exhibit an uncleaved
PCR fragment of 310 bp. Heterozygous samples show all
three fragments of 310, 233, and 77 bp, respectively. BsrbI-
treated PCR products were analyzed by electrophoresis
through 6% polyacrylamide gels (Novex, San Diego, CA,
USA) followed by Sybr Green staining (Nucleic Acid Gel
Stain, Molecular Probe, Eugene, OR, USA). All samples
showing the homozygous mutant genotype were retested
in an independent RFLP analysis.
Statistical analyses
The SAS for Windows (release 8.2) statistical software
was used for all analyses (SAS Institute Inc., Cary, NC,
USA). We described important patient characteristics us-
ing mean values and standard deviations, or medians and
the 25th/75th percentiles for continuous variables, and
percentages for categorical variables. As the distribu-
tions of plasma vitamin B12, folate levels, and tHcy were
found to be skewed to the right, and therefore nonnor-
mally distributed, we used a special case of general linear
models for all advanced analyses: the link function was
chosen to be linear and spread was determined to fol-
low a gamma distribution (in SAS, PROC GENMOD,
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Table 2. Characteristics of 729 kidney graft recipients
Variable MTHFR 1793GG MTHFR 1793GA/AA
Mean (SD) or counts (%) N = 655 N = 74
Age years 52.0 (±13.6) 50.0 (±12.5)
Male gender 399 (60.9%) 39 (52.7%)
Body mass index kg/m2 25.3 (±4.2) 25.5 (±5.0)
Estimated glomerular filtration rate mL/min/1.73 m2 56.1 (±19.8) 55.3 (±22.3)
Years since transplantation 5.1 (±4.1) 4.2 (±4.0)
Plasma vitamin B12 [median (25th/75th percentile)] pmol/L 217 (168/303) 240 (184/340)
Plasma folate [median (25th/75th percentile)] nmol/L 12.9 (9.9/16.8) 14.0 (11.3/16.9)
Plasma total homocysteine [median (25th/75th percentile)] lmol/L 15.1 (12.0/19.9) 13.4 (11.0/18.0)
Likely underlying renal disease
Diabetic nephropathy 42 (6.4%) 6 (8.1%)
Glomerulonephritis 219 (33.4%) 28 (37.8%)
Interstitial nephritis 111 (17.0%) 10 (13.5%)
Polycystic kidney disease 88 (13.4%) 11 (14.9%)
Miscellaneous other kidney disease, defined 57 (8.7%) 6 (8.1%)
Kidney disease, not otherwise defined 138 (21.1%) 13 (17.6%)
All statistical comparisons between MTHFR 1793GG and 1793GA/AA were not significant (P > 0.05). For detailed comparisons of folate, vitamin B12, and total
homocysteine by MTHFR 1793 genotype, see Tables 3 and 4.
LINK = IDENTITY, DIST = GAMMA). Such an ap-
proach provides unbiased estimates of effect for pos-
itively skewed data without the need to conduct data
transformation (e.g., to a logarithmic scale) [17, 18]. Like
in previous work, we used such models both for univariate
and multivariate analyses [5, 7, 8]. Three sets of analyses
were conducted, the outcomes being plasma levels of vi-
tamin B12, folate, and tHcy concentration, respectively.
The results reflect the absolute difference in concentra-
tion of the respective dependent variable, and asymmet-
ric 95% CI are given to reflect precision and the likely
range of the true parameter given the data [19]. Con-
sistent with similar studies conducted previously, we did
not adjust for multiple testing, due to the hypothesis gen-
erating nature of this work [5, 7, 9]. Independent co-
variates included patient age (in decades), gender, time
since kidney transplantation (<2 vs. ≥2 months), and cat-
egories of underlying kidney disease (diabetic nephropa-
thy, glomerulonephritis, interstitial nephritis, polycystic
kidney disease, miscellaneous other defined, and kidney
disease not otherwise defined). We calculated each pa-
tient’s body mass index (BMI) (categorized in quintiles)
as the weight in kilograms divided by the squared height
in meters, and defined quintiles of the plasma levels of
folate and vitamin B12. For each patient, we staged re-
nal function in accordance with the Dialysis Outcomes
Quality Initiative (K/DOQI) guidelines (>90, 60 to 90,
30 to 60, and <30 mL/min/1.73 m2) [20]. We created
dummy covariates for the genotypes of MTHFR 677C>T
and 1298A>C. A single dummy covariate was created
for either heterozygosity or homozygosity of MTHFR
1793G>A, since only two patients were homozygous for
that variant. In accordance with our a priori hypothesis,
interactions between MTHFR 1793G>A and MTHFR
1298A>C genotypes were also tested for significance. All
multivariate models adjusted for age, gender, BMI, esti-
mated glomerular filtration rate (GFR), time since trans-
plantation, underlying kidney disease, MTHFR 677C>T
and MTHFR 1298A>C genotype, plasma levels of vi-
tamin B12 (in models of plasma folate and tHcy), and




The allele frequency of MTHFR 1793G>A among all
730 patients was 0.052. Seventy-two patients (9.9%) were
heterozygous and two patients (0.3%) were homozygous.
Six hundred and fifty-six patients (89.9%) were found to
have no mutation (the one patient who was later dropped
from the association studies was in this wild-type group)
[11]. The assumption of a Hardy-Weinberg equilibrium
was not violated for this mutation (P = 0.98) [21]. The
distribution of combinations of MTHFR 1793G>A and
1298A>C genotypes is shown in Table 1 [11]. The preva-
lence of MTHFR 677C>T and 1298A>C as well as associ-
ation studies of these genotypes with the three outcomes
of interest have been published in detail elsewhere [5, 11,
12].
The mean age in the sample of 729 kidney transplant
recipients who were used for the association studies was
51.8 years, 60% were male, and more than half of the pa-
tients were obese or overweight (i.e., BMI >25 kg/m2).
Approximately 50% (N = 364) of the patients had ele-
vated tHcy (>15 lmol/L), only one patient (0.1%) was
below reference for plasma folate (<3.4 nmol/L), and
65 patients (8.9%) had vitamin B12 levels below the ref-
erence threshold (<118 pmol/L). Table 2 lists impor-
tant patient characteristics stratified by MTHFR 1793
genotype. None of these characteristics differed between
the groups (all P > 0.05). Immunosuppressive treatment
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Table 3. Plasma vitamin B12, folate and total homocysteine (tHcy)
concentrations of 729 kidney transplant recipients by MTHFR 1793
genotype (mean ± SD)
MTHFR 1793G>A genotype
GG GA AA
Number 655 72 2
Plasma vitamin B12 pmol/L 255 ± 157 274 ± 153 226 ± 41
Plasma folate nmol/L 14.4 ± 9.8 18.3 ± 27.3 20.8 ± 8.0
Plasma tHcy lmol/L 17.2 ± 8.4 16.5 ± 11.5 14.8 ± 3.7
in this study population has been described in detail
elsewhere [22]; there were no differences between the
two MTHFR 1793 groups.
Effect of MTHFR 1793G>A genotype on plasma vita-
min B12 concentrations
Mean plasma concentrations of vitamin B12 stratified
by MTHFR 1793G>A genotype are shown in Table 3.
Univariate analyses did not reveal any associations be-
tween MTHFR 1793GA/AA vs. the wild-type and plasma
vitamin B12. Similarly, after multivariate adjustment for
age, gender, BMI, estimated GFR, time since transplanta-
tion, underlying kidney disease, MTHFR 677C>T geno-
type, and plasma levels of folate, there were no differ-
ences in vitamin B12 concentrations by MTHFR 1793
genotype (Table 4). When testing for effect modification
between MTHFR 1298A>C and MTHFR 1793G>A, we
found statistically significant interactions between these
mutations. The 53 patients who carried the MTHFR al-
lelic combination 1298AC and 1793GA or 1793AA (see
Table 1) had vitamin B12 concentrations that were 171
pmol/L higher (95% CI 74 to 268 pmol/L) (P < 0.001)
and the 19 patients with MTHFR 1298CC and 1793GA
or 1793AA had vitamin B12 concentrations that were 117
pmol/L higher (95% CI 6 to 228 pmol/L) (P = 0.04) com-
pared to patients who showed wild-type alleles (Table 5).
These findings remained robust whether or not we ex-
cluded folate from these models.
Effect of MTHFR 1793G>A genotype on plasma folate
concentrations
Mean plasma levels of folate stratified by MTHFR
1793G>A genotypes are shown in Table 3, and it ap-
peared that folate concentrations were higher in patients
who were heterozygous or homozygous for the mutant al-
lele. From univariate linear regression analyses, we found
that patients with the 1793GA or AA genotype had fo-
late concentrations that were 3.91 nmol/L higher, on av-
erage, than patients with wild-type alleles (95% CI 1.89
to 5.94 nmol/L) (P < 0.001). Multivariate regression ad-
justment (for included variables see Table 4) attenuated
this finding and the difference was of borderline signifi-
cance (1.91 nmol/L) (95% CI −0.03 to 3.86 nmol/L) (P =
0.05). No interactions between MTHFR 1298A>C and
MTHFR 1793G>A were found. Excluding vitamin B12
plasma level from the multivariate regression analysis did
not change these results.
Effect of MTHFR 1793G>A genotype on plasma tHcy
concentrations
Mean tHcy plasma levels sorted by MTHFR 1793G>A
genotype are indicated in Table 3. When testing whether
MTHFR 1793GA/AA was associated with tHcy plasma
levels compared to MTHFR 1793GG in regression mod-
els, we did not detect any significant associations in uni-
variate or in multivariate analyses (Table 4). There was no
detectable interaction between MTHFR 1298A>C and
MTHFR 1793G>A. These results did not change ma-
terially whether or not we included vitamin B12 and/or
folate in the multivariate models.
DISCUSSION
The present report constitutes the first study of the
putative influence of a novel polymorphism, MTHFR
1793G>A, on important biochemical parameters of Hcy
metabolism. In a large population of kidney transplant
recipients, we found that patients carrying the MTHFR
1793G>A mutation had approximately 4 nmol/L higher
plasma folate concentrations, on average, when com-
pared to individuals with the corresponding wild-type al-
leles. Furthermore, patients who had both the MTHFR
1793G>A and the MTHFR 1298A>C mutation exhib-
ited markedly higher plasma vitamin B12 levels compared
to patients without these mutations.
Our finding of higher folate concentrations in patients
with mutations in MTHFR 1793G>A may have implica-
tions for the prognosis of these patients. Different folate
derivatives (e.g., 5,10-methylenetetrahydrofolate; 5-
formiminotetrahydrofolate; 5,10-methenyltetrahdro-
folate; 10-formyltetrahydrofolate; and 5-methyltetra-
hydrofolate) are essential coenzymes for the conversion
of serine to glycine, the catabolism of histidine, the
synthesis of purine and thymidylate, as well methio-
nine synthesis. The synthesis of methionine and thus
remethylation of Hcy is accomplished via 5-methyltetra-
hydrofolate that represents the principal folate deriva-
tive present in human serum [23]. Activated methionine
(S-adenoslymethionine), in turn, acts as a methyl donor
for numerous methyltransferases present in human
cells (examples for methylated products are lipids,
myelin basic protein, dopamine, DNA) [24]. Clearly, if
folate status is low, reduced acitivity of folate enzymes
can result in pathology (e.g., anemia) via reduction
of DNA biosynthesis and cell division [24, 25]. In this
context, it is important to mention that we used a
competitive protein binding assay (SimulTRAC-SNB)
which includes the pteroylglutamic acid form of folate
(PGA) as a standard and tracer at an binding pH where
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Table 4. Estimated univariate and multivariate linear associations between MTHFR 1793 genotype and plasma vitamin B12, folate, and total
homocysteine (tHcy) levels
Univariate results Multivariate resultsaOutcome modeled
by MTHFR genotype Estimate 95% CI P value Estimate 95% CI P value
Plasma vitamin B12 (B12 in pmol/L) (B12 in pmol/L)
1793GG — (referent) — — (referent) —
1793GA/AA 18 (−14; 51) 0.27 17 (−17; 51) 0.33
Plasma folate (delta folate in nmol/L) (folate in nmol/L)
1793GG — (referent) — — (referent) —
1793GA/AA 3.91 (1.89; 5.94) <0.001 1.91 (−0.03; 3.86) 0.05
Plasma tHcy (tHcy in lmol/L) (tHcy in lmol/L)
1793GG — (referent) — — (referent) —
1793GA/AA −0.67 (−2.31; 0.97) 0.42 −0.24 (−1.45; 0.98) 0.70
aAll multivariate models simultaneously accounted for age, gender, body mass index, estimated glomerular filtration rate, time since transplantation, underlying
kidney disease, MTHFR 677C>T and MTHFR 1298A>C. Plasma levels of vitamin B12 were additionally included in models of plasma folate and tHcy. Plasma levels
of folate were additionally included in models of plasma vitamin B12 and tHcy.
Table 5. Interaction of MTHFR 1793G>A and 1298A>C on vitamin
B12 concentrations
Estimate
Genotype (B12 in pmol/L) 95% CI P value
1793GG and 1298AA — (referent) —
(wild-type)
1793GG and 1298AC −14 (−36; 9) 0.23
1793GG and 1298CC 6 (−37; 48) 0.80
1793GA/AA and 1298AC 171 (74; 268) <0.001
1793GA/AA and 1298CC 117 (6; 228) 0.04
Multivariate results. MTHFR 1793GA/AA and 1298AA not estimated (small
cell count) (N = 2).
both 5-methyltetrahydrofolate in the sample and PGA
have equal affinity for the milk folate-binding protein.
Therefore, the higher folate levels observed among pa-
tients with the MTHFR 1793G>A mutation most likely
represent 5-methyltetrahydrofolate concentrations and
thus constitute the active folate derivative involved in
methionine synthesis.
While MTHFR 1793G>A was associated with higher
folate concentrations in this study, there was no as-
sociation with tHcy plasma concentrations. However,
mean tHcy plasma concentrations were 17.2 lmol/L, 16.5
lmol/L, and 14.8 lmol/L in patients with the MTHFR
1793GG (wild-type), 1793GA, and 1793AA genotype
suggesting a tendency toward lower tHcy concentrations
in patients with the MTHFR 1793G>A mutation who
had higher folate levels. Furthermore, while an increased
tHcy plasma concentration is a sensitive marker of fo-
late and vitamin B12 deficiency [26], tHcy concentrations
could be more tightly balanced when folate and vitamin
B12 supplies are adequate. In kidney transplant recipients,
tHcy has been shown to be associated with adverse out-
comes such as cardiovascular events, mortality, and possi-
bly increased allograft failure [22, 27]. To our knowledge,
associations between folate and such outcomes have not
yet been reported.
Most interestingly, we found that patients who tested
positive for MTHFR 1793G>A as well as MTHFR
1298A>C (double or triple mutation combination)
had higher plasma vitamin B12 concentrations when
compared with patients who did not carry these al-
lelic variants. Vitamin B12 concentrations in patients
with the MTHFR 1298AC/1793GA and the MTHFR
1298CC/1793GA or 1793AA genotypes were 171 pmol/L
and 117 pmol/L higher, respectively (Table 5). It is well
established that folate and vitamin B12 metabolism are
closely linked by the reaction that transfers a methyl
group from 5-methyltetrahydrofolate to vitamin B12 [28].
This linkage has been observed among patients with fo-
late deficiency who can exhibit low serum vitamin B12
levels in about one third of cases [29]. Conversely, in cases
of cobalamin deficiency, folate levels can be low [30].
The mechanisms by which MTHFR 1793G>A, and
MTHFR 1793G>A together with MTHFR 1298A>C, re-
sult in increased folate and vitamin B12 concentrations,
respectively, are unclear. In this context, our group pre-
viously observed that combinations of mutant MTHFR
1298 and 1793 alleles are more prevalent among the
same 730 kidney transplant patients than could be ex-
pected under an assumption of statistical independence
[11]. We identified 53 patients (expected 33.6) with the
MTHFR 1298AC/1793GA genotype, and 17 patients (ex-
pected 6.7) with the MTHFR 1298CC/1793GA genotype,
numbers that were greater than the expected cell counts
(Table 1). Furthermore, the number of patients with dou-
ble homozygosity for MTHFR 1793G>A and MTHFR
1298A>C (MTHFR 1298CC/1793AA genotype) (N =
2) was greater than expected (Table 1). Our observation
of a higher prevalence of these genotype combinations
suggested a selection or survival advantage for individ-
uals showing these genotype combinations, which might
be related to the higher concentrations of vitamin B12
described in the present study.
The present study has certain limitations. Findings from
a population of renal transplant patients may not be rep-
resentative of other populations. The cross-sectional de-
sign makes it possible that time-related biases are oper-
ational, most important survival bias. Certain genotype
combinations might affect eligibility for transplantation
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or patient survival so that such patients are less likely
to be represented in the analysis. However, such a bias
would solely influence prevalence estimates of various
genotypes, but not necessarily associations between al-
lelic variants and folate or tHcy plasma levels. We did
not assess dietary intake of folate, which should not be
an issue, because none of the patients received folic acid
or multivitamin supplements and so dietary folate intake
can be assumed to be within a relatively narrow range. Fi-
nally, we neither used a microbiologic assay for estimation
of folate supply, nor was red blood cell folate measured.
From this first study of the associations between the
novel polymorphism MTHFR 1793G>A and important
factors of homocysteine metabolism, we found that any
presence of this polymorphism was associated with higher
folate concentration in kidney transplant patients. Fur-
ther, we found evidence for an interaction between
MTHFR 1793G>A and 1298A>C. Patients who had
both the MTHFR 1793G>A and the 1298A>C mutant
allelic variant of that gene showed significantly higher
vitamin B12 concentrations. While higher concentrations
of folate and vitamin B12 might play a role in a possible
survival/selection advantage in these patients, the clini-
cally more relevant parameter of tHcy was unaffected by
these genotypes. Confirmation of these findings in inde-
pendent populations as well as studies of these genotypes
and long-term outcomes are warranted.
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